Substance use & recovery

ASAM Dimension 5: Weighing the Pull to Use Again

Save

The fifth ASAM dimension looks at relapse and continued-use potential. It shapes how much structure a treatment setting needs to provide, from a weekly outpatient visit to a monitored residential stay. Understanding what it captures helps explain why two people with the same diagnosis can land in very different levels of care.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What does ASAM Dimension 5 assess?

Dimension 5 assesses relapse, continued use, or continued problem potential — the likelihood that a person returns to substance use, and their ability to see it coming and cope. An assessor listens for how strong and frequent cravings are, what has triggered use before, how past attempts to stop have gone, and whether the person can name the situations that put them at risk. The ASAM Criteria organize a full assessment across six dimensions, and this one is where the immediate future is weighed 1.

Relapse potential is not a character judgment. It is a clinical estimate of risk, drawn from a person's own history and current state, used to decide how much support the next stretch of recovery will need. Two people with the same diagnosis can score very differently here — one with strong coping skills and a stable week, one facing daily cravings and a house full of triggers.

Why relapse potential changes your level of care

Higher relapse potential generally points toward a setting with more structure, because structure is what protects someone during the window when the pull to use is strongest. The ASAM Criteria are built to match assessed severity to a level of care rather than to a fixed program, so a high Dimension 5 rating can move a recommendation from weekly outpatient toward intensive outpatient, a day program, or a residential stay 1.

The logic runs in both directions. Someone whose cravings are manageable and whose environment is calm may do well with a lighter touch, freeing the more intensive settings for those who need them. This is why the asam levels of care are described as a continuum, not a ladder everyone climbs. The goal is a fit — enough support to hold the person, without more restriction than the moment calls for.

Why returning to use after time away is more dangerous

A relapse after a period of abstinence is often more dangerous than continued use, because tolerance falls during time away. Research on people leaving incarceration found that overdose risk is sharply elevated in the first weeks after release, driven in part by lowered tolerance after enforced abstinence 2. The same physiology applies after detox, a hospital stay, or any stretch without the drug: the dose a body once handled can become an overdose.

This is why Dimension 5 weighs relapse potential so heavily — the risk is not just a setback but, for opioids and some other drugs, a life-threatening event. It is also why forced abstinence without ongoing treatment can raise danger rather than lower it. A safety net matters here. Naloxone, an FDA-approved overdose-reversal medication, is one such net, and having it on hand is a standard part of planning for anyone at risk of an opioid relapse 3.

How medication changes relapse risk

For opioid use disorder, medication is the single most effective way to lower relapse potential, and Dimension 5 planning often centers on it. The ASAM National Practice Guideline recommends treating opioid use disorder with methadone or buprenorphine rather than withdrawal management alone, notes that no medication should be withheld because someone is still using other substances, and holds that treatment should not be arbitrarily time-limited 4.

The way a medication is started matters for relapse risk too. In a large randomized trial, extended-release naltrexone was harder to initiate than buprenorphine-naloxone because it requires a completed detox first, which led to more early failures before treatment even began; once each medication was successfully started, both were similarly safe and effective 5. The barrier for naltrexone was getting on it, not the medication itself once initiated 5. That induction gap is exactly the kind of relapse risk a good assessment plans around.

Cravings, triggers, and coping skills

Much of Dimension 5 is a practical conversation about what pulls a person toward use and what helps them resist. An assessor asks about the people, places, feelings, and times of day tied to past use, how intense the cravings get, and what has worked before — whether that is a phone call, a meeting, a medication, or simply leaving a room. These are the raw materials of a relapse-prevention plan.

The point is not to produce a perfect score but to understand a person's current toolkit. Someone who can already name their triggers and has a few reliable ways to cope carries lower relapse potential than someone who cannot yet see the pattern. Coping skills can be built, which is part of what treatment does — so this dimension is a snapshot of a moving target, not a fixed sentence. Readiness to change, weighed in a separate dimension, sits close beside it.

A lapse is not a failed treatment

A return to use is common in the course of a chronic condition and does not mean treatment failed or that a person is beyond help. SAMHSA defines recovery as a process of change toward improved health, self-direction, and reaching one's potential, and names 'many pathways' among its guiding principles 6. A single pathway rarely runs in a straight line.

What a lapse does signal is useful information: that the current level of support may not be enough, that a trigger went unaddressed, or that a medication plan needs revisiting. In dimensional terms, it is a reason to reassess Dimension 5, not a reason to give up. Many people find that a relapse, met with a prompt adjustment rather than shame, becomes the point where a plan finally fits.

How Dimension 5 fits with the other dimensions

Dimension 5 is never read alone. It sits alongside acute intoxication and withdrawal potential in the first dimension, biomedical conditions in the second, and emotional and cognitive health in the third, plus readiness to change and living environment. A person with high relapse potential and an unstable home may need more than either factor alone would suggest.

That is the design of the ASAM continuum of care: several angles on one person, combined into a placement that reflects the whole picture. When someone is trying to understand why a particular level of care was recommended — or why a request seems off — Dimension 5 is often the piece doing the heavy lifting, because it speaks to what happens next.

Common questions

It is the part of an addiction assessment that estimates how likely a person is to return to substance use, and how well they can recognize and cope with cravings and triggers. A higher rating generally points toward a treatment setting with more structure and support during the period when the pull to use is strongest.

Not automatically. Dimension 5 is one of six dimensions, and placement reflects the whole picture. A high relapse rating can push toward more structure, but a calm environment, strong coping skills, or effective medication can offset it. The aim is a fit, not the most restrictive setting available.

Tolerance drops during any period without the drug, so a dose the body once handled can become an overdose. Overdose risk is especially high in the first weeks after enforced abstinence, such as after detox or incarceration. For opioids, keeping naloxone on hand is a standard safety step.

For opioid use disorder, yes — methadone and buprenorphine are the guideline-recommended treatments and substantially reduce return to use. Guidelines also say medication should not be withheld because someone is still using other substances, and should not be arbitrarily time-limited. Medication is often central to a Dimension 5 plan.

No. A return to use is common in a chronic condition and is treated as information, not failure. It usually signals that the level of support or the plan needs adjusting. Recovery is defined as a process with many pathways, and few of them run in a straight line.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When relapse becomes an emergency

  • —Slow or stopped breathing, blue or gray lips or fingertips, or a person who cannot be woken after suspected opioid use
  • —A relapse to opioids after any period of abstinence, when tolerance is lowered and overdose risk is highest
  • —Thoughts of suicide or of not wanting to be alive alongside a return to use

For a suspected overdose, call 911 and give naloxone if it is available. For thoughts of suicide, call or text 988 for the Suicide and Crisis Lifeline.

This article is educational and does not replace an individual assessment by a licensed clinician. Relapse potential is evaluated person by person; a professional assessment is the right way to decide what level of care and what medication plan fit your situation.

References

  1. 1.American Society of Addiction Medicine (2024). The ASAM Criteria. American Society of Addiction Medicine (ASAM). link ✓That the ASAM Criteria assess patients across six dimensions and match a level of care to assessed severity along a continuum rather than to a fixed program.
  2. 2.Binswanger IA, Nowels C, Corsi KF, et al. (2012). Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addiction Science & Clinical Practice. doi:10.1186/1940-0640-7-3 ✓That overdose risk is sharply elevated in the first weeks after release from incarceration, driven in part by lowered tolerance during enforced abstinence.
  3. 3.National Institute on Drug Abuse (2024). Overdose Reversal Medications. National Institute on Drug Abuse (NIDA), NIH. link ✓That FDA-approved overdose-reversal medications such as naloxone exist and are used to reverse an opioid overdose.
  4. 4.American Society of Addiction Medicine (2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update. American Society of Addiction Medicine (ASAM). link ✓That the guideline recommends treating opioid use disorder with methadone or buprenorphine rather than withdrawal management alone, that no medication should be withheld because of ongoing use of other substances, and that medication should not be arbitrarily time-limited.
  5. 5.Lee JD, Nunes EV, Novo P, et al. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. The Lancet. doi:10.1016/S0140-6736(17)32812-X ✓That extended-release naltrexone is harder to initiate than buprenorphine-naloxone because it requires completed detox first, causing more early induction failures, but once successfully initiated both were similarly safe and effective.
  6. 6.Substance Abuse and Mental Health Services Administration (2012). SAMHSA's Working Definition of Recovery. SAMHSA. link ✓That SAMHSA defines recovery as a process of change toward improved health, self-direction, and reaching one's potential, with 'many pathways' among its guiding principles.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library